Clinical Trial Update: Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus [Phase 2]

View source ↗

Summary

Phase 2 study results assess the efficacy and safety of neramexane for treating congenital idiopathic nystagmus and acquired nystagmus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Nystagmus
• Congenital Idiopathic Nystagmus

Drugs mentioned

• Neramexane (neramexane)

Snippet

Sponsor: Merz Pharmaceuticals GmbH | Conditions: Nystagmus, Congenital Idiopathic, Nystagmus, Acquired | Phase 2 | Status: COMPLETED